1. Home
  2. AEYE vs RLYB Comparison

AEYE vs RLYB Comparison

Compare AEYE & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioEye Inc.

AEYE

AudioEye Inc.

HOLD

Current Price

$8.05

Market Cap

75.0M

Sector

Technology

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.67

Market Cap

86.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEYE
RLYB
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.0M
86.6M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
AEYE
RLYB
Price
$8.05
$16.67
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$14.63
N/A
AVG Volume (30 Days)
60.3K
25.5K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
30.56
N/A
EPS
N/A
6.16
Revenue
$40,311,000.00
$858,000.00
Revenue This Year
$11.12
N/A
Revenue Next Year
$11.45
N/A
P/E Ratio
N/A
$2.75
Revenue Growth
14.52
43.00
52 Week Low
$5.31
$0.48
52 Week High
$16.39
$17.57

Technical Indicators

Market Signals
Indicator
AEYE
RLYB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
AEYE
RLYB

About AEYE AudioEye Inc.

AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: